Joel L Weissfeld1, Wei Liu1, Corinne Woods1, Rongmei Zhang2, Jie Li1, Theresa H van der Vlugt3, Shelley R Slaughter3. 1. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. 2. Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. 3. Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
Abstract
OBJECTIVE: We aimed to provide information through 2015 about use in the United States of estrogen products, including orally and vaginally administered products, in postmenopausal women. METHODS: We used prescription claims for US commercial health insurance to calculate, in women 50 years of age or older (n = 12,007,364), the age-standardized and age-specific annual prevalence of estrogen use, by formulation and route of administration, for the period 2006 through 2015. RESULTS: The age-standardized annual prevalence of a prescription claim for oral estrogens declined over time, from 83 per 1,000 women in 2007 to 42 per 1,000 women in 2015. The age-standardized annual prevalence of a prescription claim for vaginal estrogens peaked in 2011, at 42 per 1,000 women, before declining to 35 per 1,000 women in 2015. The age-standardized annual prevalence of a prescription claim for transdermal estrogen fluctuated between 15 and 17 per 1,000 women. In age groups under 65 years of age, annual prevalence rates for vaginal rings and inserts declined over the latter half of the study period. CONCLUSIONS: Analyses of US prescription claims data between 2006 and 2015 for women 50 years of age or older showed declining use of oral estrogen generally and vaginally administered estrogen products specifically in age groups less than 65 years of age.
OBJECTIVE: We aimed to provide information through 2015 about use in the United States of estrogen products, including orally and vaginally administered products, in postmenopausal women. METHODS: We used prescription claims for US commercial health insurance to calculate, in women 50 years of age or older (n = 12,007,364), the age-standardized and age-specific annual prevalence of estrogen use, by formulation and route of administration, for the period 2006 through 2015. RESULTS: The age-standardized annual prevalence of a prescription claim for oral estrogens declined over time, from 83 per 1,000 women in 2007 to 42 per 1,000 women in 2015. The age-standardized annual prevalence of a prescription claim for vaginal estrogens peaked in 2011, at 42 per 1,000 women, before declining to 35 per 1,000 women in 2015. The age-standardized annual prevalence of a prescription claim for transdermal estrogen fluctuated between 15 and 17 per 1,000 women. In age groups under 65 years of age, annual prevalence rates for vaginal rings and inserts declined over the latter half of the study period. CONCLUSIONS: Analyses of US prescription claims data between 2006 and 2015 for women 50 years of age or older showed declining use of oral estrogen generally and vaginally administered estrogen products specifically in age groups less than 65 years of age.
Authors: Sybil L Crawford; Carolyn J Crandall; Carol A Derby; Samar R El Khoudary; L Elaine Waetjen; Mary Fischer; Hadine Joffe Journal: Menopause Date: 2018-12-21 Impact factor: 2.953
Authors: Ross L Prentice; Aaron K Aragaki; Rowan T Chlebowski; Shanshan Zhao; Garnet L Anderson; Jacques E Rossouw; Robert Wallace; Hailey Banack; Aladdin H Shadyab; Lihong Qi; Beverly M Snively; Margery Gass; JoAnn E Manson Journal: Am J Epidemiol Date: 2020-09-01 Impact factor: 4.897
Authors: Anne Marie McCarthy; Tara Friebel-Klingner; Sarah Ehsan; Wei He; Michaela Welch; Jinbo Chen; Despina Kontos; Susan M Domchek; Emily F Conant; Alan Semine; Kevin Hughes; Aditya Bardia; Constance Lehman; Katrina Armstrong Journal: Cancer Med Date: 2021-08-31 Impact factor: 4.452
Authors: Ginger D Constantine; Grant Kessler; Shelli Graham; Steven R Goldstein Journal: J Womens Health (Larchmt) Date: 2018-11-28 Impact factor: 2.681